

BF Neurophysiology Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 August 2025

BF Neurophysiology Limited
CONTENTS

	Page
Director and Other Information	3
Statement of Financial Position	4
Notes to the Financial Statements	5

BF Neurophysiology Limited
DIRECTOR AND OTHER INFORMATION

Director	Ms. Alma O'Donnell
Company Secretary	Ms. Marie-Therese Bolger
Company Number	589068
Registered Office and Business Address	47, Danieli Road Artane Dublin
Accountants	Walsh Business Consulting Certified Public Accountants Belfrye House 3A St. Brendans Avenue Artane Dublin 5 D05 Y161 Ireland
Bankers	Bank of Ireland

BF Neurophysiology Limited

STATEMENT OF FINANCIAL POSITION

as at 31 August 2025

	2025	2024
	€	€
Current assets	9,800	17,163
Creditors: amounts falling due within one year	(8,363)	(15,589)
Net Current Assets	1,437	1,574
Total Assets less Current Liabilities	1,437	1,574
Accruals and deferred income	(1,471)	(1,471)
Net (Liabilities)/Assets	(34)	103
Capital and Reserves	(34)	103

The financial statements have been prepared in accordance with the micro-companies' regime and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime".

I as Director of BF Neurophysiology Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014 (as a micro company). The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

Approved by the Director and authorised for issue on 23 February 2026 :

Ms. Alma O'Donnell
Director

BF Neurophysiology Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

1. General Information

BF Neurophysiology Limited is a company limited by shares incorporated in Ireland. 47, Danieli Road, Artane, Dublin is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Director's Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

Turnover

Turnover comprises the invoice value of services supplied by the company.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Appropriation of Income Statement	2025 €	2024 €
Profit brought forward	3	3
(Loss)/profit for the financial year	(137)	-
(Loss)/Profit carried forward	(134)	3

4. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

5. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 23 February 2026.